ArticleThe Lancet. Infectious diseases2025
Global, regional, and national burden of upper respiratory infections and otitis media, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.
Article in The Lancet. Infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 71 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The Burden of Respiratory Syncytial Virus in Children With Acute Otitis Media: A Systematic Review and Meta-Analysis.Influenza and other respiratory viruses · 2026Pooled it
- Comparative efficacy and safety of probiotic for respiratory tract infections in children: a network meta-analysis.Frontiers in nutrition · 2026Pooled it
- The influence of weather and urban environment characteristics on upper respiratory tract infections: a systematic review.Frontiers in public health · 2025Pooled it
- Host factors associated with respiratory particle emission and virus presence within respiratory particles: a systematic review.Frontiers in microbiology · 2025Pooled it
- A probiotic containing L. plantarum and P. acidilactici strains for treating upper respiratory infection in children aged 6 months to 5 years: a randomized, double-blind trial.European journal of pediatrics · 2025Trial
- Myxovirus resistance protein A to differentiate between viral and non-viral respiratory infections in adults: a prospective study.Emerging microbes & infections · 2026Article
- Seasonal and Age-Stratified Patterns of Influenza, COVID-19, and RSV in Poland (2024-2026).Viruses · 2026Article
- A decade of endemic human coronaviruses: epidemiological patterns and clinical significance in an adult cohort at a tertiary care hospital in Germany.BMC infectious diseases · 2026Article
- Global Burden of Upper Airway Infections: Epidemiology, Current Challenges and Future Perspectives.Infectious disease reports · 2026Review
- Antibacterial and Immunomodulatory Effects ofMicroorganisms · 2026Article
- Etiological characterization of acute respiratory tract infections and associated co-infections using Biofire respiratory 2.1 Plus panel.BMC infectious diseases · 2026Article
- Distinguishing common respiratory pathogens using machine learning of symptom profiles to prioritize diagnostic testing.PLOS digital health · 2026Article
- The Impact of Milk Protein Allergy on Pediatric Otitis Media Incidence.The Laryngoscope · 2026Article
- Comparison of the Clinical Course of Viral Respiratory Infections in Hospitalized Patients During the 2025/2026 Season in Poland.Vaccines · 2026Article
- Antibiotic Resistance Profiles of Invasive Bacterial Isolates from Hospitalized Pediatric Patients in Serbia: A Multicenter Surveillance Study, 2020-2024.Antibiotics (Basel, Switzerland) · 2026Article
- Long-Term Exposure to Particulate Matter 2.5 and Ozone and the Risk of Acute Respiratory Infections: Community-Based Prospective Cohort Study.JMIR public health and surveillance · 2026Article
- Artificial intelligence risk prediction model for common respiratory pathogens in China based on heterogeneous multi-source clinical and geographic data: A modeling study.PLOS digital health · 2026Article
- Randomized, Double-Blind, Placebo-Controlled Clinical Trial Assessing the Efficacy ofMicroorganisms · 2026Article
- Epidemiological characteristics and seasonal dynamics of six respiratory pathogens in children: a 2-year retrospective cross-sectional study in Chengdu, China.BMC pediatrics · 2026Article
- Association between serum vitamin A and E status and recurrent respiratory tract infections in children: a propensity score-matched study.BMC pediatrics · 2026Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUpper respiratory infections (URIs) are the leading cause of acute disease incidence worldwide and contribute to a substantial health-care burden. Although acute otitis media is a common complication of URIs, the combined global burden of URIs and otitis media has not been studied comprehensively. We used results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 to explore the fatal and non-fatal burden of the two diseases across all age groups, including a granular analysis of children younger than 5 years, in 204 countries and territories from 1990 to 2021.
methodsMortality due to URIs and otitis media was estimated with use of vital registration and sample-based vital registration data, which are used as inputs to the Cause of Death Ensemble model to separately model URIs and otitis media mortality by age and sex. Morbidity was modelled with a Bayesian meta-regression tool using data from published studies identified via systematic reviews, population-based survey data, and cause-specific URI and otitis media mortality estimates. Additionally, we assessed and compared the burden of otitis media as it relates to URIs and examined the collective burden and contributing risk factors of both diseases.
findingsThe global number of new episodes of URIs was 12·8 billion (95% uncertainty interval 11·4 to 14·5) for all ages across males and females in 2021. The global all-age incidence rate of URIs decreased by 10·1% (-12·0 to -8·1) from 1990 to 2019. From 2019 to 2021, the global all-age incidence rate fell by 0·5% (-0·8 to -0·1). Globally, the incidence rate of URIs was 162 484·8 per 100 000 population (144 834·0 to 183 289·4) in 2021, a decrease of 10·5% (-12·4 to -8·4) from 1990, when the incidence rate was 181 552·5 per 100 000 population (160 827·4 to 206 214·7). The highest incidence rates of URIs were seen in children younger than 2 years in 2021, and the largest number of episodes was in children aged 5-9 years. The number of new episodes of otitis media globally for all ages was 391 million (292 to 525) in 2021. The global incidence rate of otitis media was 4958·9 per 100 000 (3705·4 to 6658·6) in 2021, a decrease of 16·3% (-18·1 to -14·0) from 1990, when the incidence rate was 5925·5 per 100 000 (4371·8 to 8097·9). The incidence rate of otitis media in 2021 was highest in children younger than 2 years, and the largest number of episodes was in children aged 2-4 years. The mortality rate of URIs in 2021 was 0·2 per 100 000 (0·1 to 0·5), a decrease of 64·2% (-84·6 to -43·4) from 1990, when the mortality rate was 0·7 per 100 000 (0·2 to 1·1). In both 1990 and 2021, the mortality rate of otitis media was less than 0·1 per 100 000. Together, the combined burden accounted for by URIs and otitis media in 2021 was 6·86 million (4·24 to 10·4) years lived with disability and 8·16 million (4·99 to 12·0) disability-adjusted life-years (DALYs) for all ages across males and females. Globally, the all-age DALY rate of URIs and otitis media combined in 2021 was 103 per 100 000 (63 to 152). Infants aged 1-5 months had the highest combined DALY rate in 2021 (647 per 100 000 [189 to 1412]), followed by early neonates (aged 0-6 days; 582 per 100 000 [176 to 1297]) and late neonates (aged 7-24 days; 482 per 100 000 [161 to 1052]).
interpretationThe findings of this study highlight the widespread burden posed by URIs and otitis media across all age groups and both sexes. There is a continued need for surveillance, prevention, and management to better understand and reduce the burden associated with URIs and otitis media, and research is needed to assess their impacts on individuals, communities, economies, and health-care systems worldwide.
fundingBill & Melinda Gates Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.